AZN - Astrazeneca plc - ADR
IEX Last Trade
87.62
0.320 0.365%
Share volume: 2,836,761
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$87.30
0.32
0.37%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-10 | 2023-02-21 | 2023-04-27 | 2023-07-28 | 2023-11-09 | 2024-02-20 | 2024-04-25 | 2024-07-25 | |
| Assets | |||||||||
| Total Assets | 94.185 B | 96.483 B | 96.687 B | 96.543 B | 96.086 B | 101.119 B | 102.293 B | 104.340 B | |
| Current Assets | 20.224 B | 22.593 B | 22.266 B | 22.839 B | 22.501 B | 25.054 B | 25.594 B | 25.393 B | |
| Inventories | 5.078 B | 4.699 B | 4.967 B | 5.051 B | 5.292 B | 5.424 B | 5.337 B | 5.667 B | |
| Other Current Assets | 187.000 M | 87.000 M | 40.000 M | 44.000 M | 97.000 M | 116.000 M | 11.000 M | 28.000 M | |
| Short Term Investments | 187.000 M | 87.000 M | 40.000 M | 44.000 M | 97.000 M | 116.000 M | 11.000 M | 28.000 M | |
| Total Receivables | 10.061 B | 11.252 B | 10.797 B | 11.932 B | 11.997 B | 13.552 B | 12.225 B | 12.622 B | |
| Current Cash | 4.898 B | 6.405 B | 6.462 B | 5.812 B | 5.115 B | 5.962 B | 8.021 B | 7.076 B | |
| Total Non-current Assets | 73.961 B | 73.890 B | 74.421 B | 73.704 B | 73.585 B | 76.065 B | 76.699 B | 78.947 B | |
| Property Plant Equipment | 8.352 B | 8.507 B | 8.644 B | 8.675 B | 8.723 B | 9.402 B | 9.411 B | 9.630 B | |
| Other Assets | 1.779 B | 1.851 B | 1.753 B | 1.864 B | 1.889 B | 2.131 B | 2.163 B | 2.226 B | |
| Intangible Assets | 39.585 B | 39.307 B | 39.291 B | 38.326 B | 37.687 B | 38.089 B | 38.834 B | 39.426 B | |
| Goodwill | 19.707 B | 19.820 B | 20.001 B | 19.960 B | 19.939 B | 20.048 B | 19.978 B | 21.060 B | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 94.185 B | 96.483 B | 96.687 B | 96.543 B | 96.086 B | 101.119 B | 102.293 B | 104.340 B | |
| Total liabilities | 59.051 B | 59.446 B | 60.898 B | 59.151 B | 58.889 B | 61.976 B | 64.848 B | 64.828 B | |
| Total current liabilities | 24.850 B | 26.293 B | 24.860 B | 26.375 B | 28.588 B | 30.542 B | 28.901 B | 28.566 B | |
| Accounts Payable | 17.694 B | 19.040 B | 19.210 B | 19.738 B | 20.542 B | 22.374 B | 19.699 B | 20.463 B | |
| Other liabilities | 7.021 B | 6.498 B | 5.575 B | 4.901 B | 4.556 B | 5.345 B | 5.050 B | 4.669 B | |
| Current long term debt | 5.618 B | 5.542 B | 3.857 B | 4.787 B | 5.607 B | 5.400 B | 6.331 B | 5.359 B | |
| Long term debt | 23.681 B | 23.690 B | 27.646 B | 25.051 B | 22.969 B | 23.222 B | 28.220 B | 28.174 B | |
| Other liabilities | 7.021 B | 6.498 B | 5.575 B | 4.901 B | 4.556 B | 5.345 B | 5.050 B | 4.669 B | |
| Minority interest | 20.000 M | 21.000 M | 22.000 M | 24.000 M | 24.000 M | 23.000 M | 56.000 M | 86.000 M | |
| Total Shareholder equity | 35.134 B | 37.037 B | 35.789 B | 37.392 B | 37.197 B | 39.143 B | 37.445 B | 39.512 B | |
| Common stock | 3.096 B | 3.094 B | 3.098 B | 3.100 B | 3.098 B | 3.096 B | 3.098 B | 3.100 B | |
| Retained earnings | -2.471 B | -574.000 M | -1.825 B | -234.000 M | -434.000 M | 1.502 B | -212.000 M | 1.847 B |